Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1558

1.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2019 Jan 10;176(1-2):404. doi: 10.1016/j.cell.2018.12.034. No abstract available.

PMID:
30633907
2.

Mission-oriented translational cancer research - health economics.

Jönsson B, Sullivan R.

Mol Oncol. 2019 Jan 10. doi: 10.1002/1878-0261.12440. [Epub ahead of print] Review.

3.

High Throughput Strategies for the Discovery and Optimization of Catalytic Reactions.

Isbrandt ES, Sullivan RJ, Newman SG.

Angew Chem Int Ed Engl. 2018 Dec 21. doi: 10.1002/anie.201812534. [Epub ahead of print]

PMID:
30576045
4.

18F-FDG Cardiac PET inflammation imaging in a canine model of radiation induced cardiac disease associated with breast cancer radiotherapy.

El-Sherif O, Xhaferllari I, Sykes J, Butler J, deKemp RA, Renaud J, Yin H, Wilk B, Sullivan R, Pickering JG, Battista J, Wisenberg G, Prato FS, Gaede S.

Am J Physiol Heart Circ Physiol. 2018 Dec 21. doi: 10.1152/ajpheart.00273.2018. [Epub ahead of print]

PMID:
30575441
5.

Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society.

Lacombe D, Bogaerts J, Tombal B, Maignen F, Osipienko L, Sullivan R, Golfinopoulos V.

Mol Oncol. 2018 Dec 18. doi: 10.1002/1878-0261.12431. [Epub ahead of print] Review.

6.

Clinical characterization of colitis arising from anti-PD-1 based therapy.

Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB.

Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019.

PMID:
30546965
7.

The microRNA miR-7a-5p ameliorates ischemic brain damage by repressing α-synuclein.

Kim T, Mehta SL, Morris-Blanco KC, Chokkalla AK, Chelluboina B, Lopez M, Sullivan R, Kim HT, Cook TD, Kim JY, Kim H, Kim C, Vemuganti R.

Sci Signal. 2018 Dec 11;11(560). pii: eaat4285. doi: 10.1126/scisignal.aat4285.

PMID:
30538177
8.

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.

Nature. 2019 Jan;565(7738):E4. doi: 10.1038/s41586-018-0814-7.

PMID:
30532003
9.

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.

Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN.

Cancer. 2018 Dec 6. doi: 10.1002/cncr.31889. [Epub ahead of print]

PMID:
30521084
10.

Weighing false hope in population anti-cancer drug decision-making.

Chamberlain C, Sullivan R.

Ann Oncol. 2018 Nov 21. doi: 10.1093/annonc/mdy508. [Epub ahead of print] No abstract available.

PMID:
30462161
11.

Developing a Research Agenda for Adult Palliative Care: A Modified Delphi Study.

Sullivan R, Ugalde A, Sinclair C, Breen LJ.

J Palliat Med. 2018 Nov 21. doi: 10.1089/jpm.2018.0462. [Epub ahead of print]

PMID:
30461347
12.

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.

Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP, Miloslavsky EM, Kohler MJ, Sullivan RJ, Schoenfeld SR.

Semin Arthritis Rheum. 2018 Oct 16. pii: S0049-0172(18)30442-6. doi: 10.1016/j.semarthrit.2018.10.012. [Epub ahead of print]

PMID:
30409415
13.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038. Erratum in: Cell. 2019 Jan 10;176(1-2):404.

PMID:
30388456
14.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.

PMID:
30388455
15.

Meta-analysis of aberrant post-error slowing in substance use disorder: implications for behavioral adaptation and self-control.

Sullivan RM, Perlman G, Moeller SJ.

Eur J Neurosci. 2018 Nov 1. doi: 10.1111/ejn.14229. [Epub ahead of print] Review.

PMID:
30383336
16.

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ.

Melanoma Res. 2019 Feb;29(1):65-69. doi: 10.1097/CMR.0000000000000527.

PMID:
30376465
17.

Reply to emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes.

Faje AT, Sullivan RJ.

Cancer. 2018 Dec 15;124(24):4732. doi: 10.1002/cncr.31786. Epub 2018 Oct 23. No abstract available.

PMID:
30351493
18.

Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning.

Begum M, Lewison G, Jassem J, Mixich V, Cufer T, Nurgozhin T, Shabalkin P, Kutluk T, Voko Z, Radosavljevic D, Vrdoljiak E, Eniu A, Walewski J, Aggarwal A, Lawler M, Sullivan R.

Eur J Cancer. 2018 Nov;104:127-136. doi: 10.1016/j.ejca.2018.08.024. Epub 2018 Oct 20.

PMID:
30347288
19.

Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0247-8.

PMID:
30333558
20.

A Novel Web-Based Experiential Learning Platform for Medical Students (Learning Moment): Qualitative Study.

Sheng AY, Chu A, Biancarelli D, Drainoni ML, Sullivan R, Schneider JI.

JMIR Med Educ. 2018 Oct 17;4(2):e10657. doi: 10.2196/10657.

21.

The value of European immigration for high-level UK research and clinical care: cross-sectional study.

Begum M, Lewison G, Lawler M, Sullivan R.

J R Soc Med. 2018 Oct 10:141076818803427. doi: 10.1177/0141076818803427. [Epub ahead of print]

PMID:
30304641
22.

The impact of Brexit on UK cancer research.

Lawler M, Begum M, Lewison G, Aggarwal A, Selby P, Sullivan R.

Lancet Oncol. 2018 Oct;19(10):1276-1278. doi: 10.1016/S1470-2045(18)30518-7. Epub 2018 Oct 1. No abstract available.

PMID:
30303111
23.

Intelligence and global health: assessing the role of open source and social media intelligence analysis in infectious disease outbreaks.

Bernard R, Bowsher G, Milner C, Boyle P, Patel P, Sullivan R.

Z Gesundh Wiss. 2018;26(5):509-514. doi: 10.1007/s10389-018-0899-3. Epub 2018 Feb 10.

24.

Spinocerebellar ataxia: an update.

Sullivan R, Yau WY, O'Connor E, Houlden H.

J Neurol. 2018 Oct 3. doi: 10.1007/s00415-018-9076-4. [Epub ahead of print]

PMID:
30284037
25.

Developmental transitions in amygdala PKC isoforms and AMPA receptor expression associated with threat memory in infant rats.

Opendak M, Zanca RM, Anane E, Serrano PA, Sullivan RM.

Sci Rep. 2018 Oct 2;8(1):14679. doi: 10.1038/s41598-018-32762-y.

26.

Mind the Graph: Foregone Health Gains in Lung Cancer.

Cameron L, Sullivan R, Luey B, Solomon B.

Semin Oncol. 2018 Oct;45(5-6):316-317. doi: 10.1053/j.seminoncol.2017.11.004. Epub 2017 Dec 6. No abstract available.

PMID:
30262394
27.

Mechanisms of Resistance to Immune Checkpoint Blockade.

Liu D, Jenkins RW, Sullivan RJ.

Am J Clin Dermatol. 2018 Sep 26. doi: 10.1007/s40257-018-0389-y. [Epub ahead of print] Review.

PMID:
30259383
28.

Vitamin D deficiency is associated with reduced hippocampal volume and disrupted structural connectivity in patients with mild cognitive impairment.

Al-Amin M, Bradford D, Sullivan RKP, Kurniawan ND, Moon Y, Han SH, Zalesky A, Burne THJ.

Hum Brain Mapp. 2019 Feb 1;40(2):394-406. doi: 10.1002/hbm.24380. Epub 2018 Sep 25.

PMID:
30251770
29.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.

JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.

PMID:
30242316
30.

Financial Impact of Complex Cancer Surgery in India: A Study of Pancreatic Cancer.

Basavaiah G, Rent PD, Rent EG, Sullivan R, Towne M, Bak M, Sirohi B, Goel M, Shrikhande SV.

J Glob Oncol. 2018 Sep;(4):1-9. doi: 10.1200/JGO.17.00151.

31.

Palliative Care Program Development in a Low- to Middle-Income Country: Delivery of Care by a Nongovernmental Organization in India.

Krishnan A, Rajagopal MR, Karim S, Sullivan R, Booth CM.

J Glob Oncol. 2018 Sep;(4):1-8. doi: 10.1200/JGO.17.00168.

32.

Cancer Care for Refugees and Displaced Populations: Middle East Conflicts and Global Natural Disasters.

El Saghir NS, Soto Pérez de Celis E, Fares JE, Sullivan R.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):433-440. doi: 10.1200/EDBK_201365. Review.

PMID:
30231320
33.

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.

Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L.

J Thorac Oncol. 2018 Dec;13(12):1906-1918. doi: 10.1016/j.jtho.2018.08.2027. Epub 2018 Sep 11.

PMID:
30217492
34.

UK newspaper reporting of the NHS cancer drugs fund, 2010 to 2015: a retrospective media analysis.

Lewison G, Aggarwal A, Roe P, Møller H, Chamberlain C, Sullivan R.

J R Soc Med. 2018 Oct;111(10):366-373. doi: 10.1177/0141076818796802. Epub 2018 Sep 13.

35.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.

Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS.

Melanoma Res. 2018 Dec;28(6):605-610. doi: 10.1097/CMR.0000000000000509.

PMID:
30211813
36.

Increases in plasma corin levels following experimental myocardial infarction reflect the severity of ischemic injury.

Wang D, Gladysheva IP, Sullivan RD, Fan TM, Mehta RM, Tripathi R, Sun Y, Reed GL.

PLoS One. 2018 Sep 7;13(9):e0202571. doi: 10.1371/journal.pone.0202571. eCollection 2018.

37.

Posterior Thoracic Stab Wounds: Evaluating the Value of Commonly Used Radiologic Modalities.

Brigode WM, Masteller M, Chaudhuri R, Sullivan R, Vafa A.

Am Surg. 2018 Aug 1;84(8):1363-1367.

PMID:
30185317
38.

DNA repair in trinucleotide repeat ataxias.

Yau WY, O'Connor E, Sullivan R, Akijian L, Wood NW.

FEBS J. 2018 Oct;285(19):3669-3682. doi: 10.1111/febs.14644. Epub 2018 Sep 10. Review.

PMID:
30152109
39.

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.

Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, Shaham M, Rivlin A, Omer I, Zinger A, Elias S, Winter E, Erdman PE, Sullivan RW, Fung L, Mercurio F, Li D, Vacca J, Kaushansky N, Shlush L, Oren M, Levine R, Pikarsky E, Snir-Alkalay I, Ben-Neriah Y.

Cell. 2018 Sep 20;175(1):171-185.e25. doi: 10.1016/j.cell.2018.07.045. Epub 2018 Aug 23.

PMID:
30146162
40.

Early life trauma increases threat response of peri-weaning rats, reduction of axo-somatic synapses formed by parvalbumin cells and perineuronal net in the basolateral nucleus of amygdala.

Santiago AN, Lim KY, Opendak M, Sullivan RM, Aoki C.

J Comp Neurol. 2018 Nov 1;526(16):2647-2664. doi: 10.1002/cne.24522. Epub 2018 Oct 18.

PMID:
30136731
41.

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E.

Nat Med. 2018 Oct;24(10):1545-1549. doi: 10.1038/s41591-018-0157-9. Epub 2018 Aug 20. Erratum in: Nat Med. 2018 Dec;24(12):1942.

PMID:
30127394
42.

The contribution of Cyprus to non-communicable diseases and biomedical research from 2002 to 2013: implications for evidence-based health policy.

Pallari E, Lewison G, Pallari CT, Samoutis G, Begum M, Sullivan R.

Health Res Policy Syst. 2018 Aug 17;16(1):82. doi: 10.1186/s12961-018-0355-4.

43.

A randomized usability assessment of simulated naloxone administration by community members.

Eggleston W, Podolak C, Sullivan RW, Pacelli L, Keenan M, Wojcik S.

Addiction. 2018 Dec;113(12):2300-2304. doi: 10.1111/add.14416. Epub 2018 Sep 11.

PMID:
30107641
44.

Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres.

Sirohi B, Chalkidou K, Pramesh CS, Anderson BO, Loeher P, El Dewachi O, Shamieh O, Shrikhande SV, Venkataramanan R, Parham G, Mwanahamuntu M, Eden T, Tsunoda A, Purushotham A, Stanway S, Rath GK, Sullivan R.

Lancet Oncol. 2018 Aug;19(8):e395-e406. doi: 10.1016/S1470-2045(18)30342-5. Review.

PMID:
30102234
45.

A roadmap for restoring trust in Big Data.

Lawler M, Morris AD, Sullivan R, Birney E, Middleton A, Makaroff L, Knoppers BM, Horgan D, Eggermont A.

Lancet Oncol. 2018 Aug;19(8):1014-1015. doi: 10.1016/S1470-2045(18)30425-X. No abstract available.

PMID:
30102210
46.

Maternal Regulation of Pups' Cortical Activity: Role of Serotonergic Signaling.

Courtiol E, Wilson DA, Shah R, Sullivan RM, Teixeira CM.

eNeuro. 2018 Jul 31;5(4). pii: ENEURO.0093-18.2018. doi: 10.1523/ENEURO.0093-18.2018. eCollection 2018 Jul-Aug.

47.

Reply: Immunosuppression Does Not Reduce Antitumor Efficacy.

Mahmood SS, Sullivan RJ, Reynolds KL, Neilan TG.

J Am Coll Cardiol. 2018 Aug 7;72(6):702. doi: 10.1016/j.jacc.2018.06.005. No abstract available.

48.

Increased transport of acetyl-CoA into the endoplasmic reticulum causes a progeria-like phenotype.

Peng Y, Shapiro SL, Banduseela VC, Dieterich IA, Hewitt KJ, Bresnick EH, Kong G, Zhang J, Schueler KL, Keller MP, Attie AD, Hacker TA, Sullivan R, Kielar-Grevstad E, Arriola Apelo SI, Lamming DW, Anderson RM, Puglielli L.

Aging Cell. 2018 Oct;17(5):e12820. doi: 10.1111/acel.12820. Epub 2018 Jul 27.

49.

The role of targeted therapy for melanoma in the immunotherapy era.

Sullivan RJ.

Semin Cutan Med Surg. 2018 Jun;37(2):112-119. doi: 10.12788/j.sder.2018.021.

PMID:
30040088
50.

Mapping the European cancer research landscape: An evidence base for national and Pan-European research and funding.

Begum M, Lewison G, Lawler M, Sullivan R.

Eur J Cancer. 2018 Sep;100:75-84. doi: 10.1016/j.ejca.2018.04.017. Epub 2018 Jul 4.

Supplemental Content

Loading ...
Support Center